X4 Pharmaceuticals

X4 PHARMACEUTICALS INC

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Irving,,Texas,,Usa,-,March,20,,2022:,Unitedhealthcare,Sign,On

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

XFOR

Top 3 Health Care Stocks That May Rocket Higher In April

Meta Platforms Inc.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

biotech shutter

Biotech

Equities

Previews

ARWR

DSKYF

NTLA

REGN

VRNA

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc Warrants (12/04/2024)

Press Releases

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Earnings

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host  Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Health Care

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

General

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Abpro Hldgs

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Ernexa Therapeutics

Evaxion

Geovax Labs

HOOKIPA Pharma

Imunon

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

MEI Pharma

Marker Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

Portage Biotech

Rallybio

SAB Biotherapeutics

Synlogic

Unity Biotechnology

HC Wainwright & Co.

Cantor Fitzgerald

Stifel

B. Riley Securities

Comments

X4 Pharmaceuticals

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell